Towards an RTS,S-based, multi-stage, multi-antigen vaccine against falciparum malaria: Progress at the Walter Reed Army Institute of Research

Vaccine

Volumn 23, Issue 17-18, 2005, Pages 2243-2250

  Heppner Jr , D Gray ^a   Kester, Kent E ^a   Ockenhouse, Christian F ^a   Tornieporth, Nadia ^b   Ofori, Opokua ^b   Lyon, Jeffrey A ^a   Stewart, V Ann ^a   Dubois, Patrice ^b,k   Lanar, David E ^a   Krzych, Urszula ^a   Moris, Philippe ^b   Angov, Evelina ^a   Cummings, James F ^a   Leach, Amanda ^b   Hall, B Ted ^a   Dutta, Sheetij ^a   Schwenk, Robert ^a   Hillier, Collette ^a   Barbosa, Arnoldo ^a   Ware, Lisa A ^a   Nair, Lalitha ^a   Darko, Christian A ^a   Withers, Mark R ^c   Ogutu, Bernhards ^c   Polhemus, Mark E ^c   Fukuda, Mark ^d   Pichyangkul, Sathit ^d   Gettyacamin, Montip ^d   Diggs, Carter ^e   Soisson, Lorraine ^e   Milman, Jessica ^f   Dubois, Marie Claude ^b   Garçon, Nathalie ^b   Tucker, Kathryn ^g   Wittes, Janet ^g   Plowe, Christopher V ^h   Thera, Mahamadou A ⁱ   Duombo, Ogobara K ⁱ   Pau, Maria G ^j   Goudsmit, Jaap ^j   Ballou, W Ripley ^b   Cohen, Joe ^b   more..

^a WALTER REED ARMY INSTITUTE OF RESEARCH   (United States)

^b GLAXOSMITHKLINE BIOLOGICALS   (Belgium)

^c KENYA MEDICAL RESEARCH INSTITUTE   (Kenya)

^d U S ARMY   (United States)

^e UNITED STATES AGENCY FOR INTERNATIONAL DEVELOPMENT   (United States)

^f PATH Malaria Vaccine Initiative   (United States)

^g University of Iowa   (United States)

^h UNIVERSITY OF MARYLAND   (United States)

ⁱ UNIVERSITY OF BAMAKO   (Mali)

^j CRUCELL HOLLAND BV   (Netherlands)

^k ImmunoVacc Consulting   (Belgium)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ADENOVIRUS VECTOR; ALUM 02A; ALUM 03; ALUMINUM POTASSIUM SULFATE; APICAL MEMBRANE ANTIGEN 1; CIRCUMSPOROZOITE PROTEIN; DRUG CARRIER; EPITOPE; HEPATITIS B SURFACE ANTIGEN; IMMUNOLOGICAL ADJUVANT; LIPOSOME; LIVER ANTIGEN; LIVER STAGE ANTIGEN 1; MALARIA VACCINE; MEROZOITE SURFACE PROTEIN 1; PHOSPHORYL LIPID A; PSEUDOMONAS AERUGINOSA EXOTOXIN A; PSEUDOMONAS EXOTOXIN; QS 21; RECOMBINANT VACCINE; SPOROZOITE VACCINE; UNCLASSIFIED DRUG; WATER OIL CREAM;

ARMY; CELLULAR IMMUNITY; CLINICAL TRIAL; CONFERENCE PAPER; DELAYED HYPERSENSITIVITY; DISEASE COURSE; DISEASE SEVERITY; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG FORMULATION; DRUG INDUSTRY; DRUG RESEARCH; DRUG SAFETY; DRUG TARGETING; ERYTHROCYTE; EXPRESSION VECTOR; GOVERNMENT; HEALTH CARE PLANNING; HEALTH CENTER; HUMAN; HUMORAL IMMUNITY; IMMUNIZATION; IMMUNOGENICITY; LABORATORY; LICENSING; MALARIA FALCIPARUM; MEMORY CELL; MOTIVATION; NONHUMAN; PARASITEMIA; PREVENTIVE HEALTH SERVICE; PRIORITY JOURNAL; SYMPTOMATOLOGY; VIRAL GENE THERAPY;

EID: 20044362219     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2005.01.142     Document Type: Conference Paper

References (64)

1. http://wrair-www.army.mil (cited 1 January 2005).
2. Saving lives, buying time: economics of malaria drugs in an age of resistance. Institute of Medicine of the National Academies. National Academy Press, 2004.
3. J.G. Breman, M.S. Alilio, and A. Mills Conquering the intolerable burden of malaria: what's new, what's needed: a summary Am J Trop Med Hyg 71 2 Suppl 2004 1 15
4. W.R. Ballou, M. Arevalo-Herrera, D. Carucci, T.L. Richie, G. Corradin, and C. Diggs Update on the clinical development of candidate malaria vaccines Am J Trop Med Hyg 71 2 Suppl 2004 239 247
5. J.E. Tongren, F. Zavala, D.S. Roos, and E.M. Riley Malaria vaccines: if at first you don't succeed Trends Parasitol 20 12 2004 604 610
6. D. Webster, and AV.S. Hill Progress with new malaria vaccines Bull World Health Organ 81 12 2003 902 909
7. J.B. Dame, J.L. Williams, T.F. McCutchan, J.L. Weber, R.A. Wirtz, and W.T. Hockmeyer Structure of the gene encoding the immunodominant surface antigen on the sporozoite of the human malaria parasite Plasmodium falciparum Science 225 4662 1984 593 599
8. J.E. Egan, J.L. Weber, W.R. Ballou, M.R. Hollingdale, W.R. Majarian, and D.M. Gordon Efficacy of murine malaria sporozoite vaccines: implications for human vaccine development Science 236 1987 453 456
9. J.C. Sadoff, W.R. Ballou, L.S. Baron, W.R. Majarian, R.N. Brey, and W.T. Hockmeyer Oral Salmonella typhimurium vaccine expressing circumsporozoite protein protects against malaria Science 240 1988 336 338
10. V. Enea, J. Ellis, F. Zavala, D.E. Arnot, A. Asavanich, and A. Masuda DNA cloning of Plasmodium falciparumcircumsporozoite gene: amino acid sequence of repetitive epitope Science 225 1984 628 630
11. T.R. Burkot, Z.W. Da, H.M. Geysen, R.A. Wirtz, and A. Saul Fine specificities of monoclonal antibodies against the Plasmodium falciparumcircumsporozoite protein: recognition of both repetitive and non-repetitive regions Parasite Immunol 13 1991 161 170
12. J.F. Young, W.T. Hockmeyer, M. Gross, W.R. Ballou, R.A. Wirtz, and J.H. Trosper Expression of Plasmodium falciparum circumsporozoite protein in Escherichia coli for potential use in a human malaria vaccine Science 228 1985 958 962
13. D.A. Herrington, D.F. Clyde, G. Losonsky, M. Cortesia, J.R. Murphy, and J. Davis Safety and immunogenicity in man of a synthetic peptide malaria vaccine against Plasmodium falciparumsporozoites Nature 328 1987 257 259
14. W.R. Ballou, S.L. Hoffman, J.A. Sherwood, M.R. Hollingdale, F.A. Neva, and W.T. Hockmeyer Safety and efficacy of a recombinant DNA Plasmodium falciparumsporozoite vaccine Lancet i 1987 1277 1281
15. L.F. Fries, D.M. Gordon, I. Schneider, J.C. Beier, G.W. Long, and M. Gross Safety, immunogenicity, and efficacy of a Plasmodium falciparumvaccine comprising a circumsporozoite protein repeat region peptide conjugated to Pseudomonas aeruginosatoxin A Infect Immun 60 1992 1834 1839
16. L.F. Fries, D.M. Gordon, R.L. Richards, J.E. Egan, M.R. Hollingdale, and M. Gross Liposomal malaria vaccine in humans: a safe and potent adjuvant strategy Proc Natl Acad Sci USA 89 1992 358 362
17. E. Ribi Biological activities of monophosphoryl lipid A L. Levine P.F. Bonventre I.A. Morello Microbiology 1986 American Society for Microbiology Washington
18. S.L. Hoffman, R. Edelman, J.P. Bryan, I. Schneider, J. Davis, and M. Sedegah Safety, immunogenicity, and efficacy of a malaria sporozoite vaccine administered with monophosphoryl lipid A, cell wall skeleton of mycobacteria, and squalene as adjuvant Am J Trop Med Hyg 51 1994 603 612
19. J.A. Sherwood, C.N. Oster, M. Adoyo-Adoyo, J.C. Beier, G.S. Gachihi, and P.M. Nyakundi Safety and immunogenicity of a Plasmodium falciparum sporozoite vaccine: boosting of antibody response in a population with prior natural exposure Trans R Soc Trop Med Hyg 85 1991 336 340
20. J.A. Sherwood, R.S. Copeland, K.A. Taylor, K. Abok, A.J. Oloo, and J.B. Were Plasmodium falciparum circumsporozoite vaccine immunogenicity and efficacy trial with natural challenge quantitation in an area of endemic human malaria of Kenya Vaccine 14 8 1996 817 827
21. A.E. Brown, P. Singharaj, H.K. Webster, J. Pipithkul, D.M. Gordon, and J.W. Boslego Safety, immunogenicity and limited efficacy study of a recombinant Plasmodium falciparum circumsporozoite vaccine in Thai soldiers Vaccine 12 1994 102 108
22. L. Schofield, J. Villaquiran, A. Ferreira, H. Schellekens, R. Nussenzweig, and V. Nussenzweig Interferon-gamma, CD8+ T cells and antibodies required for immunity to malaria sporozoites Nature 330 1987 664 666
23. M.F. Good, D. Pombo, I.A. Quakyi, E.M. Riley, R.A. Houghten, and A. Menon Human T-cell recognition of the circumsporozoite protein of Plasmodium falciparum: immunodominant T-cell domains map to the polymorphic regions of the molecule Proc Natl Acad Sci USA 85 1998 1199 1203
24. M.F. Good, D. Pombo, I.A. Quakyi, E.M. Riley, R.A. Houghten, and A. Menon Cytotoxic T cells specific for the circumsporozoite protein of Plasmodium falciparum Nature 334 1988 258 260
25. F. Sinigaglia, M. Guttinger, J. Kilgus, D.M. Doran, H. Matile, and H. Etlinger A malaria T-cell epitope recognized in association with most mouse and human MHC class II molecules Nature 336 1988 778 780
26. F. Sinigaglia, H. Matile, and J.R. Pink Plasmodium falciparum specific human T cell clones: evidence for helper and cytotoxic activities Eur J Immunol 17 1987 187 192
27. T. Rutgers, D. Gordon, A.M. Gatoye, M. Hollingdale, W. Hockmeyer, and M. Rosenberg Hepatitis B surface antigen as carrier matrix for the repetitive epitope of the circumsporozoite protein of Plasmodium falciparum Biotechnology 6 1988 1065 1070
28. Vreden SGS, J.P. Verhave, T. Oettinger, R.W. Sauerwein, and J.H. Meuwissen Phase I clinical trial of a recombinant malaria vaccine consisting of the circumsporozoite repeat region of Plasmodium falciparum coupled to hepatitis B surface antigen Am J Trop Med Hyg 45 1991 533 538
29. D.M. Gordon, T.W. McGovern, U. Krzych, J.C. Cohen, I. Schneider, and R. LaChance Safety, immunogenicity and efficacy of a recombinantly produced Plasmodium falciparum circumsporozoite protein/HBsAg subunit vaccine J Infect Dis 171 1995 1576 1585
30. N. Garcon, D.G. Heppner, and J. Cohen Development of RTS,S/AS02: a purified subunit-based malaria vaccine candidate formulated with a novel adjuvant Expert Rev Vaccines 2 2003 231 238
31. P. Sun, R. Schwenk, K. White, J.A. Stoute, J. Cohen, and W.R. Ballou Protective immunity induced with malaria vaccine, RTS,S, is linked to Plasmodium falciparum circumsporozoite protein-specific CD4(+) and CD8(+) T cells producing IFN-gamma J Immunol 171 12 2003 6961 6967
32. J.A. Stoute, M. Slaoui, D.G. Heppner, P. Momin, K.E. Kester, and P. Desmons A preliminary evaluation of a recombinant circumsporozoite protein malaria vaccine against Plasmodium falciparum N Engl J Med 336 1997 86 91
33. J.A. Stoute, K.E. Kester, U. Krzych, B.T. Wellde, T. Hall, and K. White Long-term efficacy and immune responses following immunization with the RTS,S malaria vaccine J Infect Dis 178 1998 1139 1144
34. K.E. Kester, D.A. McKinney, N. Tornieporth, C.F. Ockenhouse, D.G. Heppner, and T. Hall Efficacy of recombinant circumsporozoite protein vaccine regimens against experimental Plasmodium falciparum malaria J Infect Dis 183 2001 640 647
35. J.F. Doherty, M. Pinder, N. Tornieporth, C. Carton, L. Vigneron, and P. Milligan A Phase I safety and immunogenicity trial with the candidate malaria vaccine, RTS,S/SBAS2, in semi-immune adults in The Gambia Am J Trop Med Hyg 61 1999 865 868
36. K.A. Bojang, P.J. Milligan, M. Pinder, L. Vigneron, A. Alloueche, and K.E. Kester Efficacy of RTS,S/AS02 malaria vaccine against Plasmodium falciparum infection in semi-immune adult men in The Gambia: a randomised trial Lancet 358 2001 1927 1934
37. A. Alloueche, P. Milligan, D.J. Conway, M. Pinder, K. Bojang, and T. Doherty Protective efficacy of the RTS,S/AS02 Plasmodium falciparum malaria vaccine is not strain specific Am J Trop Med Hyg 68 2003 97 101
38. P.L. Alonso, J. Sacarlal, and J.J. Aponte Efficacy of the RTS,S/AS02A vaccine against Plasmodium falciparum infection and disease in young African children: randomised controlled trial Lancet 364 9443 2004 1411 1420
39. http://www.malariavaccine.org/files/010301-MVI-GSK-2-27.htm (cited 1 January 2005).
40. J.R. Davis, J.R. Murphy, S. Baqar, D.F. Clyde, D.A. Herrington, and M.M. Levine Estimate of anti-Plasmodium falciparum sporozoite activity in humans vaccinated with synthetic circumsporozoite protein (NANP)3 Trans R Soc Trop Med Hyg 83 1989 748 750
41. E.G. Rodrigues, F. Zavala, D. Eichinger, J.M. Wilson, and M. Tsuji Single immunizing dose of recombinant adenovirus efficiently induces CD8+ T cell-mediated protective immunity against malaria J Immunol 158 3 1997 1268 1274
42. E.G. Rodrigues, F. Zavala, R.S. Nussenzweig, J.M. Wilson, and M. Tsuji Efficient induction of protective anti-malaria immunity by recombinant adenovirus Vaccine 16 19 1998 1812 1817
43. E.G. Rodrigues, J. Claassen, S. Lee, J.M. Wilson, R.S. Nussenzweig, and M. Tsuji Interferon-gamma-independent CD8+ T cell-mediated protective anti-malaria immunity elicited by recombinant adenovirus Parasite Immunol 22 3 2000 157 160
44. D.H. Barouch, M.G. Pau, J.H. Custers, W. Koudstaal, S. Kostense, and M.J. Havenga Immunogenicity of recombinant adenovirus serotype 35 vaccine in the presence of pre-existing anti-Ad5 immunity J Immunol 172 10 2004 6290 6297
45. S. Kostense, W. Koudstaal, M. Sprangers, G.J. Weverling, G. Penders, and N. Helmus Adenovirus types 5 and 35 seroprevalence in AIDS risk groups supports type 35 as a vaccine vector AIDS 18 8 2004 1213 1216
46. N. Tatsis, and H.C. Ertl Adenoviruses as vaccine vectors Mol Ther 10 4 2004 616 619
47. R. Vogels, D. Zuijdgeest, R. van Rijnsoever, E. Hartkoorn, I. Damen, and M.P. de Bethune Replication-deficient human adenovirus type 35 vectors for gene transfer and vaccination: efficient human cell infection and bypass of preexisting adenovirus immunity J Virol 77 15 2003 8263 8271
48. A. Szarfman, J.A. Lyon, D. Walliker, I. Quakyi, R.J. Howard, and S. Sun Mature liver stages of cloned Plasmodium falciparum share epitopes with proteins from sporozoites and asexual blood stages Parasite Immunol 10 3 1988 339 351
49. A.F. Egan, J. Morris, G. Barnish, S. Allen, B.M. Greenwood, and D.C. Kaslow Clinical immunity to Plasmodium falciparum malaria is associated with serum antibodies to the 19-kDa C-terminal fragment of the merozoite surface antigen, PfMSP-1 J Infect Dis 173 3 1996 765 769
50. B.A. Okech, P.H. Corran, J. Todd, A. Joynson-Hicks, C. Uthaipibull, and T.G. Egwang Fine specificity of serum antibodies to Plasmodium falciparum merozoite surface protein, PfMSP-1(19), predicts protection from malaria infection and high-density parasitemia Infect Immun 72 3 2004 1557 1567
51. S.P. Chang, S.E. Case, W.L. Gosnell, A. Hashimoto, K.J. Kramer, and L.Q. Tam A recombinant baculovirus 42-kilodalton C-terminal fragment of Plasmodium falciparum merozoite surface protein 1 protects Aotus monkeys against malaria Infect Immun 64 1996 253 261
52. C.A. Darko, E. Angov, W.E. Collins, E.S. Bergmann-Leitner, A.S. Girouard, and S.L. Hitt Clinical grade Plasmodium falciparum FVO MSP1-42 expressed by Escherichia coli protects Aotus nancymai against homologous erythrocytic-stage challenge Infect Immun 73 2005 287 297
53. E. Angov, B.M. Aufiero, A.M. Turgeon, M. Van Handenhove, C.F. Ockenhouse, and K.E. Kester Development and pre-clinical analysis of a Plasmodium falciparum merozoite surface protein-1(42) malaria vaccine Mol Biochem Parasitol 128 2 2003 195 204
54. S. Pichyangkul, M. Gettayacamin, R.S. Miller, J.A. Lyon, E. Angov, and P. Tongtawe Pre-clinical evaluation of the malaria vaccine candidate P. falciparum MSP1(42) formulated with novel adjuvants or with alum Vaccine 22 29/30 2004 3831 3840
55. T. Triglia, J. Healer, S.R. Caruana, A.N. Hodder, R.F. Anders, and A.F. Cowman Apical membrane antigen 1 plays a central role in erythrocyte invasion by Plasmodium species Mol Microbiol 38 4 2000 706 718
56. O. Silvie, J.F. Franetich, S. Charrin, M.S. Mueller, A. Siau, and M. Bodescot A role for apical membrane antigen 1 during invasion of hepatocytes by Plasmodium falciparum sporozoites J Biol Chem 279 10 2004 9490 9496
57. U. Krzych, J.A. Lyon, T. Jareed, I. Schneider, M.R. Hollingdale, and D.M. Gordon T lymphocytes from volunteers immunized with irradiated Plasmodium falciparum sporozoites recognize liver and blood stage malaria antigens J Immunol 155 8 1995 4072 4077
58. S.D. Polley, T. Mwangi, C.H. Kocken, A.W. Thomas, S. Dutta, and D.E. Lanar Human antibodies to recombinant protein constructs of Plasmodium falciparum apical membrane antigen 1 (AMA1) and their associations with protection from malaria Vaccine 23 5 2004 718 728
59. R.F. Anders, P.E. Crewther, S. Edwards, M. Margetts, M.L. Matthew, and B. Pollock Immunisation with recombinant AMA-1 protects mice against infection with Plasmodium chabaudi Vaccine 16 2/3 1998 240 247
60. A.W. Stowers, M.C. Kennedy, B.P. Keegan, A. Saul, C.A. Long, and L.H. Miller Vaccination of monkeys with recombinant Plasmodium falciparum apical membrane antigen 1 confers protection against blood-stage malaria Infect Immun 70 12 2002 6961 6967
61. S. Dutta, P.V. Lalitha, L.A. Ware, A. Barbosa, J.K. Moch, and M.A. Vassell Purification, characterization, and immunogenicity of the refolded ectodomain of the Plasmodium falciparum apical membrane antigen 1 expressed in Escherichia coli Infect Immun 70 6 2002 3101 3110
62. M.R. Hollingdale, M. Aikawa, C.T. Atkinson, W.R. Ballou, G.X. Chen, and J. Li Non-CS pre-erythrocytic protective antigens Immunol Lett 25 1-3 1990 71 76
63. J.D. Kurtis, M.R. Hollingdale, A.J. Luty, D.E. Lanar, U. Krzych, and P.E. Duffy Pre-erythrocytic immunity to Plasmodium falciparum: the case for an LSA-1 vaccine Trends Parasitol 17 5 2001 219 223
64. http://www.malariavaccine.org/files/FS_WRAIR_LSA1-November-2004_FINAL.pdf (cited 29 December 2004).